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Abstract 11 
Polysaccharide storage myopathy (PSSM) was first described in 1992 in Quarter 12 
horse, Appaloosa and Paint related breeds with clinical signs of exertional 13 
rhabdomyolysis. The disease is characterized by the accumulation of excessive 14 
glycogen and diastase resistant amylopectin polysaccharide inclusions within 15 
skeletal muscle fibres. The discovery of a mutation in the glycogen synthase 1 16 
(GYS1) gene in some but not all horses with the disease suggested that PSSM 17 
represents a group of diseases with similar pathology but different aetiologies, 18 
and that the pathogenesis is more complex than initially thought. Type 1 PSSM 19 
(PSSM1) refers to horses with the GYS1 mutation and has subsequently been 20 
identified in a large number of breeds found in Europe and the North America. 21 
Clinical presentations associated with PSSM1 can vary and increased muscle 22 
enzyme activity at rest or following exercise often accompanies PSSM1, however 23 
such changes may not be present in all cases. A diagnosis of PSSM is made on the 24 
basis of histopathology or specifically PSSM1 is diagnosed by genotyping horses 25 
for the GYS1 mutation.  Cases usually respond well to management changes, in 26 
particular a diet low in starch and high in fat when it is accompanied by regular 27 
exercise.  28 
  29 
Introduction 30 
Exertional rhabdomyolysis is a syndrome of muscle damage that is usually 31 
precipitated by exercise.  Once considered a single disease entity, it is now 32 
understood to represents a common clinical presentation of several very distinct 33 
disease processes (Valberg et al. 1999).  34 
 35 
First described by Valberg et al. in 1992 in Quarter horse and Appaloosa related 36 
breeds with exertional rhabdomyolysis, PSSM has subsequently been identified in 37 
a number of different breeds found in Europe and the United States (Valentine et 38 
al. 2000; McCue  et al. 2006).  39 
  40 
Polysaccharide storage myopathy is characterized by the accumulation of 41 
excessive glycogen and diastase resistant amylopectin polysaccharide inclusions 42 
within skeletal muscle fibres (Valberg et al. 1992) (Figure 1). Unlike normal 43 
glycogen stored in muscle fibres these polysaccharide inclusions are resistant to 44 
digestion with diastase and therefore are not broken down in the normal manner. 45 
The discovery of a mutation in the glycogen synthase 1 (GYS1) gene in some but 46 
not all horses with the disease (McCue et al. 2008) suggested that PSSM is in fact 47 
a group of diseases of different aetiologies, and that the pathogenesis is more 48 
complex than initially thought. As not all horses with PSSM possess the GYS1 49 
mutation (McCue al. 2008); this led to the disease being re-classified as type 1 50 
PSSM (PSSM1) referring to individuals that possess the gene mutation, and type 2 51 
PSSM (PSSM2) for individuals that have the characteristic histopathology in their 52 
skeletal muscle but do not possess the mutant allele. Many of the earlier studies of 53 
horses with PSSM performed by Dr Valberg and co-workers are now understood 54 
to have involved horses with the GYS1 mutation and therefore refer to PSSM1 55 
(Valberg-personal communication).  It remains possible that the polysaccharide 56 
inclusions in horses with PSSM2 may be a common end-point of several different 57 
pathological processes. As more is understood about this subset of horses without 58 
the GYS1 mutation several abnormalities of glycogen metabolism may be 59 
identified and this group subdivided further, as with human glycogen storage 60 
diseases. This paper reviews our current understanding of type 1 PSSM (PSSM1; 61 
horses with the GYS1 mutation) for which a definitive test is currently available. 62 
 63 
Skeletal muscle pathology 64 
Histopathology of muscle from horses with PSSM1 reveals excessive glycogen 65 
alongside abnormal non-lysosomal bound polyglucosan bodies containing less 66 
highly branched glycogen with protein aggregates (Valentine et al. 2001; 67 
Annandale et al. 2004; McCue et al. 2009). The presence of subsarcolemmal 68 
vacuoles, predominantly in type 2 muscle fibres (those with a propensity for 69 
glycolytic metabolism) are also a common finding (Valberg et al. 1992) (Figure 1). 70 
No disruption of the important membrane associated protein dystrophin has been 71 
identified in affected horses (Naylor et al. 2012). Non-specific chronic myopathic 72 
changes such as internalised nuclei and variation in muscle fibre size are 73 
consistent with previous muscle damage and regeneration. Affected horses also 74 
have a shift in muscle fibre type from type 2x to type 2a fast twitch fibres (Naylor 75 
et al. 2012). As the disease affects type 2 muscle fibres, muscles that contain a high 76 
proportion of these fibres such as the semimembranosis or gluteal muscle are 77 
usually selected for biopsy. The severity of histopathological abnormalities will 78 
likely reflect the fibre type proportion of a particular muscle. It is intriguing that 79 
similar muscle pathology has recently been described in a large number of marine 80 
mammals, although unsurprisingly the clinical histories for these species are 81 
unknown (Sierra et al. 2012).  82 
 83 
How the characteristic polysaccharide inclusions relate to the clinical signs in 84 
patients with PSSM is unclear. There is evidence to support a metabolic defect 85 
leading to a reduction of energy availability within affected muscle fibres 86 
(Annandale et al. 2005).  This may explain the observation of clinical signs in 87 
young foals with the disease in the absence of extensive change on muscle biopsy 88 
(Byrne et al. 2000; De La Corte et al. 2002), Therefore the polysaccharide 89 
inclusions may be a co-incidental marker of the disease rather than causative. In 90 
addition, it has been proposed that the physical presence of the polysaccharide 91 
inclusions and subsarcolemmal vacuoles may disrupt the arrangement and 92 
function of the myofibrillar proteins and their attachments, a theory supported by 93 
the correlation between the severity of histopathology and muscle enzyme 94 
activity (Naylor et al. 2012).  It is difficult to reconcile the clinical improvement 95 
observed in response to management changes if physical interference was solely 96 
responsible for the clinical signs observed, as the polysaccharide inclusions do not 97 
change with such husbandry modifications. 98 
 99 
Aetiology of PSSM 100 
In contrast to Thoroughbred horses with Recurrent Exertional Rhabdomyolysis 101 
(RER) no abnormality of muscle contracture was detected in in-vitro studies of 102 
muscle from horses with PSSM, suggesting a different pathogenesis of the two 103 
diseases (Lentz et al. 1999). The absence of any derangement in the ability of 104 
affected horses to utilize glycogen or produce lactate during exercise led to the 105 
suggestion that PSSM results from abnormal glycogen storage rather than a defect 106 
affecting glycogen utilization (Valberg et al. 1999). This is also supported by the 107 
finding that the greatest increases in CK activity were observed in PSSM horses 108 
performing submaximal rather than maximal exercise (Valberg et al. 1999). 109 
Studies evaluating the role of insulin sensitivity in this abnormal glycogen storage 110 
disease have yielded conflicting results in different breeds of horses (Annandale 111 
et al. 2004; Firshman et al. 2008). Quarter horses with PSSM were shown to have 112 
increased insulin sensitivity relative to control horses (De La Corte et al. 1999; 113 
Annandale et al. 2004) whilst no difference was found between Belgian draught 114 
horses and controls (Firshman et al. 2008). These differences may reflect inherent 115 
breed differences in other genes regulating insulin sensitivity or differences in 116 
muscle fibre type proportions (Firshman et al. 2008). Suggesting that mechanisms 117 
other than heightened insulin sensitivity may be resulting in the accumulation of 118 
abnormal polysaccharide within skeletal muscle of some horses with PSSM1.  119 
 120 
There are eleven skeletal muscle glycogenoses recognized in humans, many of 121 
which produce histopathological features similar to PSSM. These diseases are 122 
associated with autosomal recessive defects in specific enzymes of glycogen 123 
metabolism, lysosomal abnormalities or defects of AMP-dependent protein kinase 124 
(DiMauro and Lamperti 2001). The clinical phenotypes observed in some of these 125 
diseases are similar to those seen in horses with PSSM1. Initial work into PSSM in 126 
the horse logically focused on evaluating the activity of these key enzymes in 127 
affected horses, however no abnormalities were identified (Valberg et al. 1998).  128 
Similarly no difference in the content of the major insulin sensitive glucose 129 
transporter GLUT4 in muscle from affected horses was found (Annandale et al. 130 
2004), although more recently many more GLUT receptors have been identified in 131 
the skeletal muscle of horses, such as GLUT8 and GLUT12 (Lacombe 2014), and 132 
their role in PSSM is yet to be evaluated. 133 
 134 
Enhanced glycogen synthesis was suggested when horses with PSSM were shown 135 
to re-synthesise glycogen more rapidly following exercise depletion than normal 136 
horses (De La Corte et al. 1999b). As normal glycogen synthesis is under the 137 
control of two enzymes; glycogen synthase and glycogen branching enzyme, an 138 
alteration in the activity of one of these enzymes would likely affect the relative 139 
branching of the glycogen molecule formed leading to an altered 3-dimensional 140 
structure (Annandale et al. 2004) that may impart a resistance to digestion with 141 
diastase. 142 
 143 
Type 1 PSSM 144 
In 2008, an autosomal dominant, gain of function, mis-sense mutation (R309H) in 145 
the glycogen synthase 1 gene (GYS1) was identified in association with many but 146 
not all cases of PSSM (McCue et al. 2008). Glycogen synthase is an enzyme 147 
responsible for the production of glycogen, by joining glucose monomers via alpha 148 
1,4 linkages, under the influence of insulin and glucose-6 phosphate. This point 149 
mutation leads to a single amino acid substitution, from arginine to histidine that 150 
results in increased glycogen synthase activity (McCue et al. 2008).  151 
 152 
To date the GYS1 mutation has been identified in a large number of breeds across 153 
Europe and North America (McCue et al. 2008b; McCue et al. 2009; Stanley et al. 154 
2009b; McCue et al. 2010; Johlig et al. 2011; Schwarz et al. 2011; Herszberg, et al. 155 
2009; Baird et al. 2010) (table 1). A particularly high prevalence has been 156 
identified in Quarter horses, Percheron and Belgian draft horses (McCue et al. 157 
2008b), whilst to the authors knowledge it remains to be identified in a pure bred 158 
Thoroughbred horse. Given that genotyping affected horses has only been 159 
commercially available for the last five years, it is highly likely that as more cases 160 
are genotyped we can expect to find the mutation in a greater range of breeds. The 161 
particularly high prevalence in hardy draught breeds led some authors to suggest 162 
that the disease phenotype may have imparted an evolutionary advantage in these 163 
breeds, which is partly supported by a recent hereditary study (McCoy et al. 2014). 164 
 165 
Clinical presentation 166 
Whilst there is a distinct correlation between the GYS1 genotype and the severity 167 
of histopathology (Naylor et al. 2012) there remains considerable variation 168 
between the clinical signs associated with PSSM1, from exertional rhabdomyolysis 169 
to vague signs of poor performance, suggesting that other genetic and 170 
environmental factors may act to modify the disease phenotype (Valberg et al. 171 
2011). McCue and co-workers have shown that the ryanodine receptor (RYR1) 172 
mutation associated with malignant hyperthermia leads to a more severe 173 
phenotype in Quarter horses with PSSM1 (McCue et al. 2009b), whilst 174 
environmental factors such as diet and exercise are known to attenuate clinical 175 
signs (Firshman et al. 2003; Ribeiro et al. 2004; Borgia et al. 2010). It is plausible 176 
that many of the previously suggested acquired causes of rhabdomyolysis, such as 177 
hormonal imbalances or anti-oxidant deficiencies may exert an effect by 178 
modifying the phenotype of an already genetically susceptible individual. 179 
 180 
Whilst many horses with PSSM1 are asymptomatic (Johlig et al. 2011; Naylor et al. 181 
2012), exertional rhabdomyolysis is the most commonly and perhaps easily 182 
recognized clinical syndrome. Exertional rhabdomyolysis was reported in over 183 
90% of affected cases in one study of horses where biopsies were obtained to 184 
investigate poor performance (McCue  et al. 2009).  In one family of Warmblood 185 
horses 59% of those with the GYS1 mutation also had a history of exertional 186 
rhabdomyolysis (Johlig et al. 2011), and those with the mutation were 7.1 times 187 
more likely to show signs of exertional rhabdomyolysis than those without. 188 
However more subtle clinical signs may easily be over-looked and these include 189 
poor performance, muscle fasciculations, muscle atrophy, gait abnormalities, 190 
generalized or pelvic limb stiffness, undiagnosed lameness, paresis or back pain 191 
(Quiroz-Rothe et al. 2002; McCue et al. 2009). Interestingly PSSM affected horses 192 
are often described as having a calm demeanor (Valberg et al. 2011). 193 
 194 
Shivers 195 
Early reports suggested a possible link between PSSM and the incidence of 196 
Shivers, a neuromuscular condition characterized by a reluctance to lift the pelvic 197 
limbs, and to back-up, often associated with fasciculations of the musculature of 198 
the pelvic limb and tail (Firshman et al. 2005). This was supported by the high 199 
prevalence of weakness in horses with PSSM and a report of two Belgian horses 200 
with weakness and Shivers that were diagnosed with severe PSSM on 201 
histopathology of skeletal muscle at post-mortem examination (Valentine et al. 202 
1999). However no association between the two conditions was identified in two 203 
larger studies of 103 Belgian draught horses (Firshman et al. 2005) or 132 204 
Warmblood horses (Hunt et al. 2008). It appears that both PSSM and Shivers are 205 
neuromuscular disorders that commonly occur in similar breeds of horses, 206 
occasionally concurrently, and that there is no causative relationship. 207 
 208 
Cardiac disturbances 209 
Human glycogenoses are often associated with specific cardiac phenotypes that 210 
contribute to exercise intolerance. In particular enhanced atrio-ventricular 211 
conduction leading to arrhythmogenesis and cardiac failure are seen (Arad et al. 212 
2005; Soliman, et al. 2008). Given that polysaccharide inclusions have been 213 
reported in the myocardium of affected horses at post-mortem examination 214 
(Valentine et al. 1997; Valentine et al. 2001; Larcher et al. 2008) and that sudden 215 
death has been described in horses with PSSM, further investigation of the cardiac 216 
phenotype of horses with PSSM1 was performed (Naylor et al. 2012b). No 217 
significant structural changes or arrhythmias were detected in affected horses 218 
when compared with matched controls (Naylor et al. 2012b). 219 
 220 
Diagnosis 221 
Resting muscle enzyme activity may be used to screen for subclinical muscle 222 
damage in possible PSSM1 cases, however increases in basal creatine kinase (CK) 223 
and aspartate transferase (AST) activity may not be observed in affected horses, 224 
particularly in those that are heterozygous for the GYS1 mutation (Naylor et al. 225 
2012). Measuring skeletal muscle enzyme activity following 20 minutes of 226 
submaximal exercise (e.g. trot and canter work) may increase the sensitivity of 227 
this assessment, particularly for horses with signs of exercise intolerance (Valberg 228 
et al. 1999). A significant difference was observed between horses with PSSM1 229 
and controls in CK activity at 4 hours post-exercise but not AST activity 4 or 24 230 
hour post-exercise in one study of Belgian draught horses (Naylor et al. 2012), 231 
whereas significantly higher post-exercise AST activities were observed in horses 232 
with PSSM1 relative to controls in an earlier study of Haflinger horses (Schwarz et 233 
al. 2011). These studies suggest that there maybe breed differences in muscle 234 
enzyme responses to exercise in horses with PSSM1 or may simply reflect small 235 
sample sizes. Furthermore the changes in muscle enzyme activity following 236 
exercise may be relatively small (increases of less than 50% above resting levels) 237 
compared to those typically seen in other diseases such as RER and importantly 238 
there is considerable overlap between the response of unaffected control horses 239 
and those heterozygous for the GYS1 mutation. Therefore raised muscle enzyme 240 
activity should increase the index of suspicion of a myopathy and prompt further 241 
investigations such as muscle biopsy or GYS1 genotyping. However, PSSM cannot 242 
be excluded in the absence of large changes of muscle enzyme activity following 243 
exercise.  244 
 245 
A diagnosis of PSSM has traditionally been made on histopathology of muscle 246 
biopsy samples, however this technique is unable to clearly differentiate between 247 
PSSM1 and PSSM2. The identification of the GYS1 mutation has allowed the 248 
development of a restriction fragment length polymorphism (RFLP) assay to 249 
diagnose type 1 PSSM (McCue et al. 2008). This is performed on DNA extracted 250 
from EDTA whole blood samples or hair roots (approximately 30 required- easily 251 
collected from the mane or tail). This assay is a less invasive method for testing for 252 
PSSM1 than the traditional muscle biopsy, and is particularly useful in breeds 253 
known to have a high prevalence of the GYS1 mutation. The blood test may also be 254 
useful in younger individuals where changes on histopathology are fewer, as it is 255 
known that the severity of the polysaccharide accumulations increases as an 256 
animal ages (De La Corte et al. 2002). Furthermore genotyping affected animals 257 
may provide useful prognostic information for making decisions with regards to 258 
training and breeding, as it has been shown that the severity of the skeletal muscle 259 
pathology correlates with the number of copies of the mutant allele with 260 
homozygotes having more severe histopathology than those heterozygous for the 261 
GYS1 mutation (Naylor et al. 2012).   262 
 263 
It is often useful to consider the breed of the animal when deciding which 264 
diagnostic test(s) to perform. In breeds with a particularly high prevalence of 265 
PSSM1 such as Draught and Quarter horse related breeds it may be preferable to 266 
genotype the horse for the GYS1 mutation initially. A particularly high prevalence 267 
is found in continental European breeds, such as the Percheron, whilst the 268 
prevalence in UK derived breeds such as the Clydesdale or Shire is much lower 269 
(McCue et al. 2010). Conversely in breeds with a lower prevalence of the GYS1 270 
mutation, such as Cobs and Welsh ponies or indeed those where the mutation has 271 
yet to be described such as Thoroughbred horses, that would more likely have 272 
PSSM2 or another myopathy, a skeletal muscle biopsy remains the most 273 
appropriate diagnostic test currently available. Skeletal muscle biopsy samples 274 
should be harvested from the gluteal or the semimembranosis muscles, and are 275 
easily obtained from the standing sedated animal (Ledwith and McGowan 2004). 276 
Biopsy samples are best preserved when placed in an empty sterile pot and 277 
transported immediately on ice packs to the laboratory (Stanley et al. 2009). It is 278 
recommended to liaise with the diagnostic laboratory prior to collecting the 279 
biopsy and avoid posting samples at the end of the week, to avoid unnecessary 280 
delays in transport.  281 
 282 
Treatment of PSSM 283 
The aim of managing horses with PSSM is to limit the constant synthesis of 284 
glycogen within skeletal muscle by reducing circulating insulin and promoting 285 
glycogen metabolism through regular exercise. In addition an alternative energy 286 
source such as fat can be provided as long as the horse is not overweight. These 287 
recommendations are based on research performed in horses with PSSM1. To date 288 
there are no controlled studies in horses with PSSM2 although it is assumed that 289 
similar recommendations apply. Regular daily exercise in addition to pasture 290 
turnout is advised, in conjunction with a diet low in starch and sugar (<10% 291 
digestible energy (DE) as non-structural carbohydrates (NSC)) and relatively high 292 
in fat (13-20% DE) (Ribeiro et al. 2004; Borgia et al. 2010). Horses should continue 293 
to receive 1-2% of their bodyweight as forage, ideally with a low (<12%) NSC 294 
content (Borgia et al. 2011) and in some cases, depending on workload and energy 295 
requirements, further caloric supplementation may not be required. Grazing may 296 
need to be restricted at certain times of the year when the NSC content of grass is 297 
particularly high. There are specifically formulated commercial diets available 298 
(such as Dodson and Horrell ERS Pellets or Saracen ReLeve), although adequate 299 
fat will only be provided if fed in quantities recommended by the manufacturers. 300 
Alternatively a low starch diet may be supplemented with vegetable oil, up to a 301 
maximum of 1ml/kg to provide sufficient calories. In some cases diets with a 302 
slightly lower fat content may be more palatable yet still be sufficient to control 303 
the condition. A high lipid diet increases the requirement for anti-oxidants, 304 
therefore a feed balancer containing vitamin E may be beneficial.   305 
 306 
The prognosis is favorable in cases where dietary and exercise recommendations 307 
are followed, and these horses are significantly more likely to have an 308 
improvement in the severity and frequency of clinical signs relative to those cases 309 
where only one (exercise of dietary) recommendation is followed (Firshman et al. 310 
2003).  A clinical improvement may be observed within 6 weeks although 311 
complete adaptation to these diets likely takes several months (Ribeiro et al. 312 
2004).  313 
 314 
Type 2 PSSM 315 
Horses with PSSM2 are not easily distinguishable from those with PSSM1 on the 316 
basis of clinical signs and histopathology, although subtle differences in the 317 
morphological appearance of polysaccharide inclusions have been suggested 318 
(McCue et al. 2009). Fine granular, often diastase negative, inclusions are 319 
frequently located close to the sarcolemma in PSSM2 as oppose to the coarse 320 
granular diastase positive granules frequently observed in PSSM1 (McCue et al. 321 
2008; McCue et al. 2009). Type 2 PSSM may be a result of one sole enzymatic 322 
defect, or perhaps more likely may reflect a group of glycogen storage diseases, 323 
with a similar histopathological end-point. Further work is needed to further 324 
elucidate the pathophysiologic process(es) involved in these horses.  325 
 326 
Conclusion 327 
Polysaccharide storage myopathy is a disease seen in a variety of breeds 328 
throughout the UK and Europe as well as North America. The particularly high 329 
prevalence of PSSM1 in some Draught breeds likely reflects a prior evolutionary 330 
advantage. The recent identification of the GYS1 mutation could allow for 331 
eradication of the disease from these breeds by the implementation of 332 
coordinated breeding programmes. This remains controversial, however, in those 333 
breeds with a low incidence of clinical signs. The clinical presentation can vary as 334 
can muscle enzyme activity in affected horses, therefore muscle biopsy and 335 
genotyping for the GYS1 mutation is required to establish a definitive diagnosis. 336 
Whilst no specific treatment is currently available affected horses usually respond 337 
well to management changes, in particular a low starch high fat diet in conjunction 338 
with regular exercise. With appropriate management the prognosis is favorable. 339 
 340 
References 341 
Annandale, E. J., Valberg, S.J. and Essen-Gustavsson, B. (2005). "Effects of 342 
submaximal exercise on adenine nucleotide concentrations in skeletal 343 
muscle fibers of horses with polysaccharide storage myopathy." Am J Vet 344 
Res 66(5): 839-845. 345 
Annandale, E. J., Valberg, S.J., Mickelson, J.R. and Seaquist, E.R. (2004). "Insulin 346 
sensitivity and skeletal muscle glucose transport in horses with equine 347 
polysaccharide storage myopathy." Neuromuscul Disord 14(10): 666-674. 348 
Arad, M., Maron, B.J., Gorham, J.M., Johnson, W.H., Saul, J.P., Perez-Atayde, A.R., 349 
Spirito, P., Wright, G.B., Kanter, R.J., Seidman, C.E. and Seidman, J.G. (2005). 350 
"Glycogen storage diseases presenting as hypertrophic cardiomyopathy." 351 
N Engl J Med 352(4): 362-372. 352 
Baird, J. D., Valberg, S.J., Anderson, S.M., McCue, M.E., Mickelson, J.R. (2010). 353 
"Presence of the glycogen synthase 1 (GYS1) mutation causing type 1 354 
polysaccharide storage myopathy in continental European draught horse 355 
breeds." Vet Rec 167(20): 781-784. 356 
Borgia, L.A., Valberg, S.J., McCue, M.E., Watts, K. and Pagan, J. (2011) Glycemic and 357 
insulinemic responses to feeding hay with different nonstructural 358 
carbohydrate content in control and Polysaccharide Storage Myopathy-359 
affected horses. J Physiol Anim Nutr 95 (6): 798-807. 360 
Borgia, L.A., Valberg, S.J., McCue, M.E., Pagan, J.D and Roe, C.R. (2010) Effect of 361 
dietary fats with odd or even numbers of carbon atoms on metabolic 362 
response and muscle damage with exercise in Quarter Horse-type horses 363 
with type 1 polysaccharide storage myopathy. Am J Vet Res 71 (3): 326-36. 364 
Byrne, E., Cohen, N., Jones, S.L., Jackson, S.L. Zimmel, D.N. and Valberg, S.J. (2000). 365 
"Rhabdomyolysis in two foals with polysaccharide storage myopathy." 366 
Compend Contin educ Pract Vet 22(5): 503-507. 367 
De La Corte, F. D., Valberg, S.J., MacLeay, J.M., Mickelson J.R. (2002). 368 
"Developmental onset of polysaccharide storage myopathy in 4 Quarter 369 
Horse foals." J Vet Intern Med 16(5): 581-587. 370 
De La Corte, F. D., Valberg, S.J., MacLeay, J.M., Williamson, S.E. and Mickelson, J.R. 371 
(1999). "Glucose uptake in horses with polysaccharide storage myopathy." 372 
Am J Vet Res 60(4): 458-462. 373 
De La Corte, F. D., Valberg, S.J. Mickelson, J.R. Hower-Moritz, M.A. and Mickelson, 374 
J.R. (1999b). "Blood glucose clearance after feeding and exercise in 375 
polysaccharide storage myopathy." Equine Vet J. Supplement 30: 324-328. 376 
DiMauro, S. and C. Lamperti (2001). "Muscle glycogenoses." Muscle & nerve 24(8): 377 
984-999. 378 
Firshman, A. M., Baird, J.D. and Valberg, S.J. (2005). "Prevalences and clinical signs 379 
of polysaccharide storage myopathy and shivers in Belgian draft horses." J 380 
Am Vet Med Ass 227(12): 1958-1964. 381 
Firshman, A. M., Valberg, S.J., Baird, J.D., Hunt, L. and DiMauro, S.  (2008). "Insulin 382 
sensitivity in Belgian horses with polysaccharide storage myopathy." Am J 383 
Vet Res 69(6): 818-823. 384 
Firshman, A. M., Valberg, S.J., Bender, J.B. and Finno, C.J. (2003). "Epidemiologic 385 
characteristics and management of polysaccharide storage myopathy in 386 
Quarter Horses." Am J Vet Res 64(10): 1319-1327. 387 
Herszberg, B., McCue, M.E., Larcher, T., Mata, X., Vaiman, A., Chaffaux, S., Cherel, Y., 388 
Valberg, S.J., Mickelson, J.R. and Guerin, G. (2009). "A GYS1 gene mutation 389 
is highly associated with polysaccharide storage myopathy in Cob 390 
Normand draught horses." Animal genetics 40(1): 94-96. 391 
Hunt, L. M., Valberg, S.J., Steffenhagen, K. and McCue, M.E. (2008). "An 392 
epidemiological study of myopathies in Warmblood horses." Equine Vet J 393 
40(2): 171-177. 394 
Johlig, L., Valberg, S.J., Mickelson, J.R., Klukowska, J., Reusser, H.R., Straub, R. and 395 
Gerber, V. (2011). "Epidemiological and genetic study of exertional 396 
rhabdomyolysis in a Warmblood horse family in Switzerland." Equine Vet 397 
J 43(2): 240-245. 398 
Lacombe, V. A. (2014). "Expression and regulation of facilitative glucose 399 
transporters in equine insulin-sensitive tissue: from physiology to 400 
pathology." Vet Sci 2014: 409547. 401 
Larcher, T., Herszberg, B., Molon-Noblot, S. Guigand, L., Chaffaux, S. Guerin, G. amd 402 
Cherel, Y. (2008). "Polysaccharide storage myopathy in Cob Normand draft 403 
horses." Vet Pathol 45(2): 154-158. 404 
Ledwith. A. and C. McGowan (2004). "Muscle biopsy: a routine diagnostic 405 
procedure." Equine Vet Ed 16(2): 62-67. 406 
Lentz, L. R., Valberg, S.J., Mickelson, J.R. and Gallant, E.M. (1999). "In vitro 407 
contractile responses and contracture testing of skeletal muscle from 408 
Quarter Horses with exertional rhabdomyolysis." Am J Vet Res 60(6): 684-409 
688. 410 
McCoy, A. M., Schaefer, R., Petersen, J.L., Morrell, P.L., Slamka, M.A., and Mickelson, 411 
J.R., Valberg, S.J. and McCue, M.E. (2014). "Evidence of positive selection for 412 
a glycogen synthase (GYS1) mutation in domestic horse populations." The 413 
Journal of Heredity 105(2): 163-172. 414 
McCue, M. E., Anderson, S.M., Valberg, S.J., Piercy, R.J., Barakzai, S.Z., Binns, M.M., 415 
Distl, O. Penedo, M.C., Wagner, M.L. and Mickelson, J.R.  (2010). "Estimated 416 
prevalence of the Type 1 Polysaccharide Storage Myopathy mutation in 417 
selected North American and European breeds." Animal Genetics 41 2: 418 
145-149. 419 
McCue, M. E., Armien, A.G., Lucio, M., Mickelson, J.R. and Valberg, S.J. (2009). 420 
"Comparative skeletal muscle histopathologic and ultrastructural features 421 
in two forms of polysaccharide storage myopathy in horses." Vet Pathol 422 
46(6): 1281-1291. 423 
McCue, M. E., Ribeiro, W.P. and Valberg, S.J. (2006). "Prevalence of polysaccharide 424 
storage myopathy in horses with neuromuscular disorders." Equine Vet J. 425 
Suppl (36): 340-344. 426 
McCue, M. E., Valberg, S.J., Jackson, M, Borgia, L., Lucio, M., Mickelson, J.R.  (2009b). 427 
"Polysaccharide storage myopathy phenotype in quarter horse-related 428 
breeds is modified by the presence of an RYR1 mutation." Neuromuscul 429 
Disord 19(1): 37-43. 430 
McCue, M. E., Valberg, S.J., Lucio, M., Mickelson, J.R. (2008b). "Glycogen synthase 1 431 
(GYS1) mutation in diverse breeds with polysaccharide storage 432 
myopathy." J Vet Intern Med 22(5): 1228-1233. 433 
McCue, M. E., Valberg, S.J., Miller, M.B., Wade, C, DiMauro, S., Akman, H.O. and 434 
Mickelson, J.R. (2008). "Glycogen synthase (GYS1) mutation causes a novel 435 
skeletal muscle glycogenosis." Genomics 91(5): 458-466. 436 
Naylor, R. J., Livesey, L. Schumacher, J., Henke, N., Massey, C., Brock, K.V., 437 
Fernandez-Fuente, M. and Piercy, R.J. (2012). "Allele copy number and 438 
underlying pathology are associated with subclinical severity in equine 439 
type 1 polysaccharide storage myopathy (PSSM1)." PloS one 7(7): e42317. 440 
Naylor, R. J., Luis-Fuentes, V., Livesey, L., Mobley, C.B., Henke, N., Brock, K.V., 441 
Fernandez-Fuente, M., and Piercy R.J. (2012b). "Evaluation of cardiac 442 
phenotype in horses with type 1 polyaccharide storage myopathy 443 
(PSSM1)." J Vet Intern Med. 444 
Quiroz-Rothe, E., Novales, M., Aguilera-Tejero, E. and Rivero, J.L. (2002). 445 
"Polysaccharide storage myopathy in the M. longissimus lumborum of 446 
showjumpers and dressage horses with back pain." Equine Vet J 34(2): 447 
171-176. 448 
Ribeiro, W. P., Valberg, S.J., Pagan, J.D., Gustavsson, B.E. (2004). "The effect of 449 
varying dietary starch and fat content on serum creatine kinase activity and 450 
substrate availability in equine polysaccharide storage myopathy." J Vet 451 
Intern Med 18(6): 887-894. 452 
Schwarz, B., Ertl, B., Zimmer, S., Netzmann, Y. Klein, D., Schwendenwein and Hoven, 453 
R.V. (2011). "Estimated prevalence of the GYS-1 mutation in healthy 454 
Austrian Haflingers." Vet Rec 169(22): 583. 455 
Sierra, E., Fernandez, A., Espinosa de Los Monteros, A., Jaber, J.R., Andrada, M. and 456 
Herraez, P. (2012). "Complex polysaccharide inclusions in the skeletal 457 
muscle of stranded cetaceans." Vet journal 193(1): 152-156. 458 
Soliman, O. I., van der Beek, N.A., van Doorn, P.A, Vletter, W.B., Nemes, A. Van Dalen, 459 
B.M., ten Cate, F.J., van der Ploeg, A.T. and Geleijnse, M.L. (2008). "Cardiac 460 
involvement in adults with Pompe disease." J Intern Med 264(4): 333-339. 461 
Stanley, R. L., Maile, C. and Piercy, R.J. (2009). "Storage-associated artefact in 462 
equine muscle biopsy samples." Equine Vet J 41(1): 82-86. 463 
Stanley, R. L., McCue, M.E., Valberg, S.L, Mickelson, J.R., Mayhew, I.G., McGowan, C., 464 
Hahn, C.N., Patterson-Kane, J.C. and Piercy, R.J. (2009b). "A glycogen 465 
synthase 1 mutation associated with equine polysaccharide storage 466 
myopathy and exertional rhabdomyolysis occurs in a variety of UK breeds." 467 
Equine Vet J 41(6): 597-601. 468 
Valberg, S. J., Cardinet, G.H. 3rd, Carlson, G.P. and DiMauro, S. (1992). 469 
"Polysaccharide storage myopathy associated with recurrent exertional 470 
rhabdomyolysis in horses." Neuromuscul Disord 2(5-6): 351-359. 471 
Valberg, S. J., Macleay, J.M., Billstrom, J.A., Hower-Moritz, M.A. and Mickelson, J.R.  472 
(1999). "Skeletal muscle metabolic response to exercise in horses with 473 
'tying-up' due to polysaccharide storage myopathy." Equine Vet J 31(1): 474 
43-47. 475 
Valberg, S. J., McCue, M.E. and Mickelson, J. (2011). "The Interplay of Genetics, 476 
Exercise, and Nutrition in Polysaccharide Storage Myopathy." Journal of 477 
Equine Veterinary Science 31: 205-210. 478 
Valberg, S. J., Mickelson, J.R., Gallant, E.M., MacLeay, J.M. and Lentz, L. (1999). 479 
"Exertional rhabdomyolysis in quarter horses and thoroughbreds: one 480 
syndrome, multiple aetiologies." Equine Vet J Suppl 30: 533-538. 481 
Valberg, S. J., Townsend, D. and Mickelson, J.R. (1998). "Skeletal muscle glycolytic 482 
capacity and phosphofructokinase regulation in horses with 483 
polysaccharide storage myopathy." Am J Vet Res 59(6): 782-785. 484 
Valentine, B. A., Credille, K.M., Lavoie, J.P., Fatone, S., Guard, C., Cummings, J.F. and 485 
Cooper, B.J. (1997). "Severe polysaccharide storage myopathy in Belgian 486 
and Percheron draught horses." Equine Vet J 29(3): 220-225. 487 
Valentine, B. A., de Lahunta, A., Divers, T.J., Ducharme, N.G. and Orcutt, R.S. (1999). 488 
"Clinical and pathologic findings in two draft horses with progressive 489 
muscle atrophy, neuromuscular weakness, and abnormal gait 490 
characteristic of shivers syndrome." J Am Vet Med Assoc 215(11): 1661-491 
1665, 1621. 492 
Valentine, B. A., Habecker, P.L., Patterson, J.S., Njaa, B.L. Shapiro, J., Holshuh, H.J., 493 
Bildfell, R.J., Bird, K.E. (2001). "Incidence of polysaccharide storage 494 
myopathy in draft horse-related breeds: a necropsy study of 37 horses and 495 
a mule." J Vet Diagn Invest 13(1): 63-68. 496 
Valentine, B. A., McDonough, S.P., Chang, Y.F. and Vonderchek, A.J. (2000). 497 
"Polysaccharide storage myopathy in Morgan, Arabian, and Standardbred 498 
related horses and Welsh-cross ponies." Vet Pathol 37(2): 193-196. 499 
 500 
  501 
Table 1: Breeds in which the GYS1 mutation has been identified in to date. 502 
Breed 
Quarter Horse 
Paint 
Appaloosa 
Warmblood 
Haflinger 
Morgan 
Mustang 
Rocky Mountain horse 
Belgian draught 
Percheron 
Shire 
Suffolk Punch 
Hanoverian 
Rhinelander 
Cob Normand 
Connemara x Welsh pony 
Connemara x Thoroughbred 
Cob 
Argentinian polo pony 
Polo pony 
South German Coldblood 
Saxon-Thuringian Coldblood 
Exmoor pony 
Continental European draught breeds 
e.g. Ardenner, Belgian trekpaard 
Crossbreds  
 503 
  530 
Figure 1: Characteristic skeletal muscle histopathology in type 1 PSSM compared 531 
with muscle from a matched control stained with a) haematoxylin and eosin 532 
showing sub-sarcolemmal vacuolation (arrow) and marked variation in fibre 533 
size, b) periodic acid Schiff (PAS) showing increased glycogen accumulation 534 
(arrow) and c) periodic acid schiff following predigestion with diastase revealing 535 
abnormal diastase-resistant polysaccharide (arrow). ×20 magnification. 536 
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